Document and Entity Information
Document and Entity Information | 12 Months Ended |
Dec. 31, 2022 | |
Cover [Abstract] | |
Document Type | DEF 14A |
Amendment Flag | false |
Entity Registrant Name | Ionis Pharmaceuticals, Inc. |
Entity Central Index Key | 0000874015 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure | 12 Months Ended | ||
Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | |
Pay vs Performance Disclosure [Table] | |||
Pay vs Performance [Table Text Block] | Pay Versus Performance Pay Versus Performance Table As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K (“ Item 402(v) Year Summary Compensation Table Total for PEO (1) Compensation Actually Paid to PEO (2) Average Summary Compensation Table Total for Non-PEO NEOs (3) Average Compensation Actually Paid to Non-PEO NEOs (4) Value of Initial Fixed $100 Investment Based On: Net Income (Loss) (7) One-Year Relative Total Shareholder Return (8) Total Shareholder Return (5) Peer Group Total Shareholder Return (6) 2022 $ 7,299,077 $ 5,033,980 $ 2,803,964 $ 2,735,368 $ 62.52 $ 113.65 ($ 269,722,000 81 st 2021 $ 13,305,673 ($ 3,095,776 $ 3,834,223 $ 713,811 $ 50.37 $ 126.45 ($ 28,597,000 41 st 2020 $ 10,963,040 $ 3,439,140 $ 5,450,933 $ 1,822,613 $ 93.59 $ 126.42 ($ 479,743,000 35 th (1) The dollar amounts reported are the amounts of total compensation reported for Dr. Monia (our Chief Executive Officer) for each corresponding year in the “Total” column of the Summary Compensation Table on page 76 of this Proxy Statement. (2) The dollar amounts represent the amount of compensation actually paid to Dr. Monia, as computed in accordance with Item 402(v). The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr. Monia during the applicable year. In accordance with the requirements of Item 402(v), the following adjustments were made to Dr. Monia’s total compensation for each year to determine the compensation actually paid: Year Reported Summary Compensation Table Total for PEO Deduct: Reported Value of Equity Awards (a) Add: Equity Award Adjustments (b) Add: Reported Change in the Actuarial Present Value of Pension Benefits (c) Add: Pension Benefit Adjustments (c) Compensation Actually Paid to PEO 2022 $ 7,299,077 ($ 5,586,119 $ 3,321,022 $ - $ - $ 5,033,980 2021 $ 13,305,673 ($ 11,986,030 ($ 4,415,419 $ - $ - ($ 3,095,776 2020 $ 10,963,040 ($ 9,620,555 $ 2,096,655 $ - $ - $ 3,439,140 (a) The grant date fair value of equity awards represents the total of the amounts reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year. (b) The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards that are granted and vest in the same applicable year, the fair value as of the vesting date; (iv) for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v) for awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi) the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. The amounts deducted or added in calculating the equity award adjustments are as follows: Year Year End Fair Value of Equity Awards Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year (i) Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year Value of Dividends or other Earnings Paid on Stock or Option Awards Not Otherwise Reflected in Fair Value or Total Compensation (ii) Total Equity Award Adjustments 2022 $ 5,731,326 ($ 2,549,358 $ - $ 326,316 ($ 187,261 $ - $ 3,321,022 2021 $ 4,655,272 ($ 8,289,894 $ - ($ 716,002 ($ 64,795 $ - ($ 4,415,419 2020 $ 7,071,074 ($ 4,319,642 $ - ($ 654,778 $ - $ - $ 2,096,655 (i) We do not grant any equity awards that vest in the same year as grant. (ii) We do not pay dividends or other earnings on stock or option awards. (c) We do not provide pension benefits to any employees of the Company. (3) The dollar amounts reported represent the average of the amounts reported for the Company’s NEOs as a group (excluding Dr. Monia) in the “Total” column of the Summary Compensation Table of the Proxy Statement for each applicable year. The names of each of the NEOs (excluding Dr. Monia) included for purposes of calculating the average amounts in each applicable year are as follows: (i) For 2022, Elizabeth L. Hougen (EVP & CFO), Joseph T. Baroldi (EVP, Chief Business Officer), Onaiza Cadoret-Manier (EVP, Chief Global Product Strategy and Operations Officer) and Richard S. Geary (EVP, Chief Development Officer); (ii) For 2021, Elizabeth L. Hougen (EVP & CFO), Patrick R. O’Neil (EVP, Chief Legal Officer and General Counsel), Onaiza Cadoret-Manier (EVP, Chief Global Product Strategy and Operations Officer) and Eric E. Swayze (EVP, Research; and (iii) For 2020, Elizabeth L. Hougen (EVP & CFO), Stanley Crooke (Executive Chairman of the Board), Richard S. Geary (EVP, Chief Development Officer) and Patrick R. O’Neil (EVP, Legal and General Counsel). (4) The dollar amounts reported represent the average amount of compensation actually paid to the NEOs as a group (excluding Dr. Monia), as computed in accordance with Item 402(v). The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the NEOs as a group (excluding Dr. Monia) during the applicable year. In accordance with the requirements of Item 402(v), the following adjustments were made to average total compensation for the NEOs as a group (excluding Dr. Monia) for each year to determine the compensation actually paid, using the same methodology described above in Note 2: Year Average Reported Summary Compensation Table Total for Non-PEO NEOs Deduct: Average Reported Value of Equity Awards Add: Average Award Adjustments (a) Add: Average Reported Change in the Actuarial Present Value of Pension Benefits (b) Add: Average Pension Benefit Adjustments (b) Average Compensation Actually Paid to Non-PEO NEOs 2022 $ 2,803,964 ($ 1,887,231 $ 1,818,634 $ - $ - $ 2,735,368 2021 $ 3,834,223 ($ 3,039,250 ($ 81,162 $ - $ - $ 713,811 2020 $ 5,450,933 ($ 4,484,784 $ 856,465 $ - $ - $ 1,822,613 (a) The amounts deducted or added in calculating the total average equity award adjustments are as follows: Year Year End Fair Value of Equity Awards Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year (i) Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year Value of Dividends or other Earnings Paid on Stock or Option Awards Not Otherwise Reflected in Fair Value or Total Compensation (ii) Total Equity Award Adjustments 2022 $ 1,962,339 ($ 164,642 $ - $ 20,938 $ - $ - $ 1,818,634 2021 $ 1,171,440 ($ 1,216,952 $ - ($ 35,650 $ - $ - ($ 81,162 2020 $ 3,366,846 ($ 2,476,142 $ - ($ 34,239 $ - $ - $ 856,465 (i) We do not grant any equity awards that vest in the same year as grant. (ii) We do not pay dividends or other earnings on stock or option awards. (b) We do not provide pension benefits to any employees of the Company. (5) Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company’s stock price at the end and the beginning of the measurement period by the Company’s stock price at the beginning of the measurement period. (6) Represents the weighted peer group TSR, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group used for this purpose is the Nasdaq Biotechnology Index. (7) The dollar amounts reported represent the amount of net income (loss) reflected in the Company’s audited financial statements for the applicable year. (8) One-year relative TSR shown is the percentile rank of the Company’s TSR as compared to the TSRs of all members of the Nasdaq Biotechnology Index, ranked in descending order, for the one-year period commencing on January 15 th th | ||
Company Selected Measure Name | One-Year Relative Total Shareholder Return | ||
Named Executive Officers, Footnote [Text Block] | (3) The dollar amounts reported represent the average of the amounts reported for the Company’s NEOs as a group (excluding Dr. Monia) in the “Total” column of the Summary Compensation Table of the Proxy Statement for each applicable year. The names of each of the NEOs (excluding Dr. Monia) included for purposes of calculating the average amounts in each applicable year are as follows: (i) For 2022, Elizabeth L. Hougen (EVP & CFO), Joseph T. Baroldi (EVP, Chief Business Officer), Onaiza Cadoret-Manier (EVP, Chief Global Product Strategy and Operations Officer) and Richard S. Geary (EVP, Chief Development Officer); (ii) For 2021, Elizabeth L. Hougen (EVP & CFO), Patrick R. O’Neil (EVP, Chief Legal Officer and General Counsel), Onaiza Cadoret-Manier (EVP, Chief Global Product Strategy and Operations Officer) and Eric E. Swayze (EVP, Research; and (iii) For 2020, Elizabeth L. Hougen (EVP & CFO), Stanley Crooke (Executive Chairman of the Board), Richard S. Geary (EVP, Chief Development Officer) and Patrick R. O’Neil (EVP, Legal and General Counsel). | ||
Peer Group Issuers, Footnote [Text Block] | (6) Represents the weighted peer group TSR, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group used for this purpose is the Nasdaq Biotechnology Index. | ||
PEO Total Compensation Amount | $ 7,299,077 | $ 13,305,673 | $ 10,963,040 |
PEO Actually Paid Compensation Amount | $ 5,033,980 | (3,095,776) | 3,439,140 |
Adjustment To PEO Compensation, Footnote [Text Block] | (2) The dollar amounts represent the amount of compensation actually paid to Dr. Monia, as computed in accordance with Item 402(v). The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr. Monia during the applicable year. In accordance with the requirements of Item 402(v), the following adjustments were made to Dr. Monia’s total compensation for each year to determine the compensation actually paid: Year Reported Summary Compensation Table Total for PEO Deduct: Reported Value of Equity Awards (a) Add: Equity Award Adjustments (b) Add: Reported Change in the Actuarial Present Value of Pension Benefits (c) Add: Pension Benefit Adjustments (c) Compensation Actually Paid to PEO 2022 $ 7,299,077 ($ 5,586,119 $ 3,321,022 $ - $ - $ 5,033,980 2021 $ 13,305,673 ($ 11,986,030 ($ 4,415,419 $ - $ - ($ 3,095,776 2020 $ 10,963,040 ($ 9,620,555 $ 2,096,655 $ - $ - $ 3,439,140 (a) The grant date fair value of equity awards represents the total of the amounts reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year. (b) The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards that are granted and vest in the same applicable year, the fair value as of the vesting date; (iv) for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v) for awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi) the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. The amounts deducted or added in calculating the equity award adjustments are as follows: Year Year End Fair Value of Equity Awards Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year (i) Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year Value of Dividends or other Earnings Paid on Stock or Option Awards Not Otherwise Reflected in Fair Value or Total Compensation (ii) Total Equity Award Adjustments 2022 $ 5,731,326 ($ 2,549,358 $ - $ 326,316 ($ 187,261 $ - $ 3,321,022 2021 $ 4,655,272 ($ 8,289,894 $ - ($ 716,002 ($ 64,795 $ - ($ 4,415,419 2020 $ 7,071,074 ($ 4,319,642 $ - ($ 654,778 $ - $ - $ 2,096,655 (i) We do not grant any equity awards that vest in the same year as grant. (ii) We do not pay dividends or other earnings on stock or option awards. (c) We do not provide pension benefits to any employees of the Company. | ||
Non-PEO NEO Average Total Compensation Amount | $ 2,803,964 | 3,834,223 | 5,450,933 |
Non-PEO NEO Average Compensation Actually Paid Amount | $ 2,735,368 | 713,811 | 1,822,613 |
Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | (4) The dollar amounts reported represent the average amount of compensation actually paid to the NEOs as a group (excluding Dr. Monia), as computed in accordance with Item 402(v). The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the NEOs as a group (excluding Dr. Monia) during the applicable year. In accordance with the requirements of Item 402(v), the following adjustments were made to average total compensation for the NEOs as a group (excluding Dr. Monia) for each year to determine the compensation actually paid, using the same methodology described above in Note 2: Year Average Reported Summary Compensation Table Total for Non-PEO NEOs Deduct: Average Reported Value of Equity Awards Add: Average Award Adjustments (a) Add: Average Reported Change in the Actuarial Present Value of Pension Benefits (b) Add: Average Pension Benefit Adjustments (b) Average Compensation Actually Paid to Non-PEO NEOs 2022 $ 2,803,964 ($ 1,887,231 $ 1,818,634 $ - $ - $ 2,735,368 2021 $ 3,834,223 ($ 3,039,250 ($ 81,162 $ - $ - $ 713,811 2020 $ 5,450,933 ($ 4,484,784 $ 856,465 $ - $ - $ 1,822,613 (a) The amounts deducted or added in calculating the total average equity award adjustments are as follows: Year Year End Fair Value of Equity Awards Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year (i) Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year Value of Dividends or other Earnings Paid on Stock or Option Awards Not Otherwise Reflected in Fair Value or Total Compensation (ii) Total Equity Award Adjustments 2022 $ 1,962,339 ($ 164,642 $ - $ 20,938 $ - $ - $ 1,818,634 2021 $ 1,171,440 ($ 1,216,952 $ - ($ 35,650 $ - $ - ($ 81,162 2020 $ 3,366,846 ($ 2,476,142 $ - ($ 34,239 $ - $ - $ 856,465 (i) We do not grant any equity awards that vest in the same year as grant. (ii) We do not pay dividends or other earnings on stock or option awards. (b) We do not provide pension benefits to any employees of the Company. | ||
Compensation Actually Paid vs. Total Shareholder Return [Text Block] | Analysis of the Information Presented in the Pay Versus Performance Table While the Company utilizes several performance measures to align executive compensation with Company performance, all of those Company measures are not presented in the Pay Versus Performance Table (“ PVP Table Compensation Actually Paid and Cumulative TSR As demonstrated by the following graph, the amount of compensation actually paid to Dr. Monia and the average amount of compensation actually paid to the Company’s NEOs as a group (excluding Dr. Monia) is aligned with the Company’s cumulative TSR over the three years presented in the table. | ||
Compensation Actually Paid vs. Net Income [Text Block] | Analysis of the Information Presented in the Pay Versus Performance Table While the Company utilizes several performance measures to align executive compensation with Company performance, all of those Company measures are not presented in the Pay Versus Performance Table (“ PVP Table Compensation Actually Paid and Net Income The graph below shows the amount of compensation actually paid to Dr. Monia and the average amount of compensation actually paid to the Company’s NEOs as a group (excluding Dr. Monia) and the Company’s net income over the three years presented in the table. As noted above, the Company does not use compensation actually paid to set executive compensation. | ||
Compensation Actually Paid vs. Company Selected Measure [Text Block] | Analysis of the Information Presented in the Pay Versus Performance Table While the Company utilizes several performance measures to align executive compensation with Company performance, all of those Company measures are not presented in the Pay Versus Performance Table (“ PVP Table Compensation Actually Paid and Relative Total Shareholder Return The graph below shows the amount of compensation actually paid to Dr. Monia and the average amount of compensation actually paid to the Company’s NEOs as a group (excluding Dr. Monia) and the Company’s one-year relative total shareholder return shown as a percentile rank of the Company’s TSR as compared to the TSRs of all members of the Nasdaq Biotechnology Index for each of the three years presented in the table. | ||
Total Shareholder Return Vs Peer Group [Text Block] | Analysis of the Information Presented in the Pay Versus Performance Table While the Company utilizes several performance measures to align executive compensation with Company performance, all of those Company measures are not presented in the Pay Versus Performance Table (“ PVP Table Cumulative TSR of the Company and Cumulative TSR of the NBI The graph below shows the Company’s cumulative TSR over the three-year period against the cumulative TSR of the peer group presented for this purpose, the Nasdaq Biotechnology Index. | ||
Tabular List [Table Text Block] | Financial Performance Measures As described in greater detail in the CD&A, we design our executive compensation program to drive the creation of long-term stockholder value and mitigate unnecessary or imprudent business risk taking. To that end, we structure our executive compensation program to align executive compensation with Company performance. The most important financial performance measures used by the Company in fiscal year 2022 to link executive compensation actually paid to the Company’s NEOs to the Company’s performance are listed in the table to the right. Most Important Financial Performance Measures Revenue Relative TSR Versus the NBI Whether We Met Our Non-GAAP Net Operating Loss Guidance | ||
Total Shareholder Return Amount | $ 62.52 | 50.37 | 93.59 |
Peer Group Total Shareholder Return Amount | 113.65 | 126.45 | 126.42 |
Net Income (Loss) | $ (269,722,000) | $ (28,597,000) | $ (479,743,000) |
Company Selected Measure Amount | 81 | 41 | 35 |
PEO Name | Dr. Monia | Dr. Monia | Dr. Monia |
Additional 402(v) Disclosure [Text Block] | All information provided above under the “Item 402(v) Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference. | ||
Measure [Axis]: 1 | |||
Pay vs Performance Disclosure [Table] | |||
Measure Name | Revenue | ||
Measure [Axis]: 2 | |||
Pay vs Performance Disclosure [Table] | |||
Measure Name | Relative TSR Versus the NBI | ||
Measure [Axis]: 3 | |||
Pay vs Performance Disclosure [Table] | |||
Measure Name | Whether We Met Our Non-GAAP Net Operating Loss Guidance | ||
PEO [Member] | Reported Value of Equity Awards [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | $ (5,586,119) | $ (11,986,030) | $ (9,620,555) |
PEO [Member] | Equity Award Adjustments [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 3,321,022 | (4,415,419) | 2,096,655 |
PEO [Member] | Year End Fair Value of Equity Awards [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 5,731,326 | 4,655,272 | 7,071,074 |
PEO [Member] | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | (2,549,358) | (8,289,894) | (4,319,642) |
PEO [Member] | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 0 | 0 | 0 |
PEO [Member] | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 326,316 | (716,002) | (654,778) |
PEO [Member] | Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | (187,261) | (64,795) | 0 |
PEO [Member] | Value of Dividends or Other Earnings Paid on Stock or Option Awards Not Otherwise Reflected in Fair Value or Total Compensation [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 0 | 0 | 0 |
PEO [Member] | Reported Change in the Actuarial Present Value of Pension Benefits [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 0 | 0 | 0 |
PEO [Member] | Pension Benefit Adjustments [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 0 | 0 | 0 |
Non-PEO NEO [Member] | Reported Value of Equity Awards [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | (1,887,231) | (3,039,250) | (4,484,784) |
Non-PEO NEO [Member] | Equity Award Adjustments [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 1,818,634 | (81,162) | 856,465 |
Non-PEO NEO [Member] | Year End Fair Value of Equity Awards [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 1,962,339 | 1,171,440 | 3,366,846 |
Non-PEO NEO [Member] | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | (164,642) | (1,216,952) | (2,476,142) |
Non-PEO NEO [Member] | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 0 | 0 | 0 |
Non-PEO NEO [Member] | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 20,938 | (35,650) | (34,239) |
Non-PEO NEO [Member] | Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 0 | 0 | 0 |
Non-PEO NEO [Member] | Value of Dividends or Other Earnings Paid on Stock or Option Awards Not Otherwise Reflected in Fair Value or Total Compensation [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 0 | 0 | 0 |
Non-PEO NEO [Member] | Reported Change in the Actuarial Present Value of Pension Benefits [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 0 | 0 | 0 |
Non-PEO NEO [Member] | Pension Benefit Adjustments [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | $ 0 | $ 0 | $ 0 |